Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

340 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Protocol for a phase IV double-blind randomised controlled trial to investigate the effect of the 13-valent pneumococcal conjugate vaccine and the 23-valent pneumococcal polysaccharide vaccine on pneumococcal colonisation using the experimental human pneumococcal challenge model in healthy adults (PREVENTING PNEUMO 2).
Liatsikos K, Hyder-Wright A, Pojar S, Chen T, Wang D, Davies K, Myerscough C, Reine J, Robinson RE, Urban B, Mitsi E, Solorzano C, Gordon SB, Quinn A, Pan K, Anderson AS, Theilacker C, Begier E, Gessner BD, Collins A, Ferreira DM; PNEUMO 2 study group. Liatsikos K, et al. Among authors: gessner bd. BMJ Open. 2022 Jul 7;12(7):e062109. doi: 10.1136/bmjopen-2022-062109. BMJ Open. 2022. PMID: 35798520 Free PMC article.
Reassessing the 1 + 1 pneumococcal conjugate vaccine schedule.
Isturiz R, Gessner BD, Madhava H, Paradiso P, Jodar L. Isturiz R, et al. Among authors: gessner bd. Lancet Infect Dis. 2018 Apr;18(4):382. doi: 10.1016/S1473-3099(18)30133-6. Epub 2018 Mar 21. Lancet Infect Dis. 2018. PMID: 29582767 No abstract available.
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, Ramirez JA, Jodar L. McLaughlin JM, et al. Among authors: gessner bd. Clin Infect Dis. 2018 Oct 30;67(10):1498-1506. doi: 10.1093/cid/ciy312. Clin Infect Dis. 2018. PMID: 29790925 Free PMC article.
A public health evaluation of 13-valent pneumococcal conjugate vaccine impact on adult disease outcomes from a randomized clinical trial in the Netherlands.
Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Neuzil KM, O'Brien KL, Wunderink RG, Grobbee DE, Bonten MJM, Jodar L. Gessner BD, et al. Vaccine. 2019 Sep 10;37(38):5777-5787. doi: 10.1016/j.vaccine.2018.05.097. Epub 2018 May 31. Vaccine. 2019. PMID: 29861177 Free article. Clinical Trial.
Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Invasive Disease Caused by Serotype 3 in Children: A Systematic Review and Meta-analysis of Observational Studies.
Sings HL, De Wals P, Gessner BD, Isturiz R, Laferriere C, McLaughlin JM, Pelton S, Schmitt HJ, Suaya JA, Jodar L. Sings HL, et al. Among authors: gessner bd. Clin Infect Dis. 2019 May 30;68(12):2135-2143. doi: 10.1093/cid/ciy920. Clin Infect Dis. 2019. PMID: 30357326 Free PMC article.
A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L. Gessner BD, et al. Vaccine. 2019 Jul 9;37(30):4147-4154. doi: 10.1016/j.vaccine.2019.05.065. Epub 2019 May 31. Vaccine. 2019. PMID: 31155413 Free article. Clinical Trial.
340 results